Ohm wrote,
Very true, but if you are putting money upfront, and don't have much or any revenue yet, I don't think some backing + cash in the form of a NASH partnership would be a bad thing. As Ohm has shown, there are so many possible indications, down the road, and such a vast market awaiting, that sacrificing a portion of one of those markets might make sense. If CYDY can go it alone, without toxic financing, so much the better. Just need revenue, either via partnership or approval.
Quote:A few million dollars [for the cost of a Phase III liver trial] isn't much in the scheme of things. 20% or more of revenue up and above what simple distribution would cost on a multi-billion dollar indication is.
Very true, but if you are putting money upfront, and don't have much or any revenue yet, I don't think some backing + cash in the form of a NASH partnership would be a bad thing. As Ohm has shown, there are so many possible indications, down the road, and such a vast market awaiting, that sacrificing a portion of one of those markets might make sense. If CYDY can go it alone, without toxic financing, so much the better. Just need revenue, either via partnership or approval.
9
